TRANSITION METAL-BASED SELECTIVE FUNCTIONALIZATION OF CHALCOGENS IN BIOMOLECULES
    4.
    发明申请
    TRANSITION METAL-BASED SELECTIVE FUNCTIONALIZATION OF CHALCOGENS IN BIOMOLECULES 审中-公开
    生物分子中过氧化物酶基因的选择性功能化

    公开(公告)号:WO2016011107A9

    公开(公告)日:2016-09-09

    申请号:PCT/US2015040495

    申请日:2015-07-15

    CPC classification number: C07K1/13 C07K1/1077

    Abstract: Disclosed are methods of selective cysteine and selenocysteine modification on peptide/protein molecules under physiologically relevant conditions. The methods feature several advantages over existing methods of peptide modification, such as specificity towards thiols and selenols over other nucleophiles (e.g., amines, hydroxyls), excellent functional group tolerance, and mild reaction conditions.

    Abstract translation: 公开了在生理相关条件下对肽/蛋白质分子进行选择性半胱氨酸和硒代半胱氨酸修饰的方法。 与现有的肽修饰方法相比,这些方法具有几个优点,例如对硫醇和硒醇比其他亲核试剂(例如胺,羟基)的特异性,优异的官能团耐受性和温和的反应条件。

    PROTECTING GROUPS USEFUL IN THE SYNTHESIS OF POLYSACCHARIDES, NATURAL PRODUCTS, AND COMBINATORIAL LIBRARIES
    6.
    发明申请
    PROTECTING GROUPS USEFUL IN THE SYNTHESIS OF POLYSACCHARIDES, NATURAL PRODUCTS, AND COMBINATORIAL LIBRARIES 审中-公开
    保护组合有利于多糖,天然产物和组合图书馆的合成

    公开(公告)号:WO0138337A3

    公开(公告)日:2001-09-07

    申请号:PCT/US0032050

    申请日:2000-11-21

    CPC classification number: C07H15/18 C07H15/203 Y02P20/55

    Abstract: One aspect of the present invention relates to optionally substituted halogenated benzyl halides and the like. These compounds are useful as halogenated benzyl ether-based protecting groups for a variety of functional groups. Another aspect of the present invention relates to use of said protecting groups in an orthogonal protecting group strategy for the synthesis of complex molecules that comprise a number of suitable functional groups. Another aspect of the present invention relates to saccharides bearing various arrays of protecting groups of the present invention. Another aspect of the present invention relates to a method of synthesizing an oligosaccharide or glycoconjugate, comprising the steps of: using a saccharide bearing at least one protecting group of the present invention to glycosylate a second molecule to give a product comprising said saccharide; and removing a protecting group of the present invention from said product.

    Abstract translation: 本发明的一个方面涉及任选取代的卤代苄基卤化物等。 这些化合物可用作各种官能团的卤代苄基醚基保护基。 本发明的另一方面涉及所述保护基团在正交保护基团策略中用于合成包含多个合适官能团的复合分子的用途。 本发明的另一方面涉及带有本发明的各种保护基阵列的糖类。 本发明的另一方面涉及寡糖或糖缀合物的合成方法,其包括以下步骤:使用具有本发明的至少一个保护基团的糖来糖基化第二分子以产生包含所述糖的产物; 并从所述产物中除去本发明的保护基团。

    TRANSITION METAL-BASED SELECTIVE FUNCTIONALIZATION OF CHALCOGENS IN BIOMOLECULES
    7.
    发明申请
    TRANSITION METAL-BASED SELECTIVE FUNCTIONALIZATION OF CHALCOGENS IN BIOMOLECULES 审中-公开
    生物分子中CHALCOGENS的金属过渡金属选择性功能化

    公开(公告)号:WO2016011107A3

    公开(公告)日:2016-03-24

    申请号:PCT/US2015040495

    申请日:2015-07-15

    CPC classification number: C07K1/13 C07K1/1077

    Abstract: Disclosed are methods of selective cysteine and selenocysteine modification on peptide/protein molecules under physiologically relevant conditions. The methods feature several advantages over existing methods of peptide modification, such as specificity towards thiols and selenols over other nucleophiles (e.g., amines, hydroxyls), excellent functional group tolerance, and mild reaction conditions.

    Abstract translation: 公开了在生理相关条件下对肽/蛋白质分子进行选择性半胱氨酸和硒代半胱氨酸修饰的方法。 该方法具有优于现有的肽修饰方法的优点,例如对硫醇和硒醇比其它亲核试剂(例如胺,羟基)的特异性,优异的官能团耐受性和温和的反应条件。

    BENZIMIDAZOLE DERIVATIVES AND USES THEREOF
    9.
    发明申请
    BENZIMIDAZOLE DERIVATIVES AND USES THEREOF 审中-公开
    苯并咪唑衍生物及其用途

    公开(公告)号:WO2014145887A1

    公开(公告)日:2014-09-18

    申请号:PCT/US2014030733

    申请日:2014-03-17

    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and pharmaceutical compositions thereof. The present invention also provides methods and kits using the inventive compounds and pharmaceutical compositions for treating and/or preventing diseases associated with protein aggregation, such as amyloidoses (e.g., Parkinson's disease and Alzheimer's disease), treating and/or preventing neurodegenerative diseases, treating and/or preventing diseases associated with Tar DNA binding protein 43 kDa, reducing or preventing protein aggregation, and/or modulating E3 ubiquitin ligase in a subject in need thereof.

    Abstract translation: 本发明提供了式(I)的新化合物及其药学上可接受的盐,溶剂化物,水合物,多晶型物,共晶体,互变异构体,立体异构体,同位素标记的衍生物,前药和药物组合物。 本发明还提供了使用本发明化合物和药物组合物治疗和/或预防与蛋白质聚集相关的疾病如淀粉样变性病(例如帕金森氏病和阿尔茨海默氏病),治疗和/或预防神经变性疾病,治疗和 /或预防有此需要的受试者中与Tar DNA结合蛋白43kDa有关的疾病,减少或防止蛋白质聚集,和/或调节E3泛素连接酶。

Patent Agency Ranking